within Pharmacolibrary.Drugs.ATC.N;

model N05AA04_1
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 2.3333333333333332e-05,
    adminDuration  = 600,
    adminMass      = 0.1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0066,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0015,
    Tlag           = 600,            
    Vdp             = 0.0053,
    k12             = 2.7,
    k21             = 2.7
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N05AA04_1</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Acepromazine is a phenothiazine derivative used primarily as a veterinary tranquilizer and sedative. It is commonly administered to dogs, cats, and horses for pre-anesthetic sedation, prevention of motion sickness, or for general tranquilization. Its use in humans is extremely rare today and primarily limited to veterinary medicine.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for acepromazine in healthy adult dogs after oral administration.</p><h4>References</h4><ol><li><p>Knych, HK, et al., &amp; Kass, PH (2018). Pharmacokinetics, pharmacodynamics, and metabolism of acepromazine following intravenous, oral, and sublingual administration to exercised Thoroughbred horses. <i>Journal of veterinary pharmacology and therapeutics</i> 41(4) 522–535. DOI:<a href=&quot;https://doi.org/10.1111/jvp.12494&quot;>10.1111/jvp.12494</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29457257/&quot;>https://pubmed.ncbi.nlm.nih.gov/29457257</a></p></li><li><p>Hashem, A, &amp; Keller, H (1993). Disposition, bioavailability and clinical efficacy of orally administered acepromazine in the horse. <i>Journal of veterinary pharmacology and therapeutics</i> 16(3) 359–368. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2885.1993.tb00183.x&quot;>10.1111/j.1365-2885.1993.tb00183.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8230407/&quot;>https://pubmed.ncbi.nlm.nih.gov/8230407</a></p></li><li><p>Hashem, A, et al., &amp; Scherkl, R (1992). [The pharmacokinetics and bioavailability of acepromazine in the plasma of dogs]. <i>DTW. Deutsche tierarztliche Wochenschrift</i> 99(10) 396–398. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1425314/&quot;>https://pubmed.ncbi.nlm.nih.gov/1425314</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N05AA04_1;
